Should You Buy Bristol-Myers Squibb Company Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Bristol-Myers Squibb Company (BMY) stands out as one of the highest-quality businesses in our coverage universe, earning a Quality of Company score of 9.0/10. At a current price of $60.74 and a market capitalization of $124.0B, the core investment question is whether the stock offers a compelling entry point relative to its estimated intrinsic value.
The short answer: 8 of 12 CirclFi valuation models project upside for Bristol-Myers Squibb Company (BMY) at $60.74 — the model consensus leans bullish, with a Quality Score of 9.0/10 and Value-Trap risk of 33/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $271.82 (+347.5% upside)
- According to the CirclFi Quality of Company (QOC) framework, Bristol-Myers Squibb Company's score of 9.0/10 reflects durable competitive advantages that should sustain earnings power through market cycles.
- According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with an average implied return of +68.8% across 7 bullish models from the current price of $60.74.
- According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model targets a fair value of $271.82 (+347.5%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
- Industry tailwind: late-stage pipeline catalysts could provide meaningful support for Bristol-Myers Squibb Company's revenue and margin trajectory in the Drug Manufacturers - General space.
- Scale advantage: as a $124.0B large-cap company, Bristol-Myers Squibb Company benefits from economies of scale, institutional investor demand, and index inclusion that smaller competitors lack.
The Bear Case
Target: $18.12 (-70.2%)
- According to the CirclFi Deep Alpha Valuation Engine, the Sentiment SOTP model sees the stock as overvalued with a fair value of $18.12 (-70.2%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +417.7% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
- Industry headwind: regulatory rejection risk represents a meaningful risk for Bristol-Myers Squibb Company and its Drug Manufacturers - General peers.
The Bottom Line
Bristol-Myers Squibb Company leans positive in our analysis — 7/12 models bullish, composite fair value of $102.55 vs. $60.74, QOC 9.0/10. The case is constructive but not overwhelming, and the 3 dissenting models shouldn't be dismissed. Position sizing should reflect this moderate conviction level.
These are quantitative model outputs, not investment recommendations. Bristol-Myers Squibb Company's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy BMY stock right now?
Based on CirclFi's multi-model analysis, 8 of 12 models see upside for BMY at $60.74. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 9.0/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Bristol-Myers Squibb Company?
Key risks include: wide model disagreement (1400% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - General companies. Always diversify and consult a financial advisor.
How does BMY compare to its competitors?
Among Drug Manufacturers - General peers, BMY holds a Quality Score of 9.0/10. Comparable companies include AZN (QOC 10.0), NVO (QOC 10.0), LLY (QOC 9.8). The relative ranking helps investors identify whether BMY offers better fundamental quality than alternatives in the same sector.
Is BMY a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. BMY's Quality Score of 9.0/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy BMY at?
CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $18.12 to $271.82. At $60.74, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for BMY.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad